Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental amyotrophic lateral sclerosis drug after a mid-stage study failed to meet its goals.
Novartis BX:NOT has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest setback for the Swiss drugmaker this year. The decision follows an earlier disappointment for a closely watched heart drug.